Honest Comparison · April 2026
REMEVi vs. Hims/Hers
We compared pricing, features, bilingual support, and safety record across both platforms. Here's exactly what we found — no spin.
Side-by-side
REMEVi vs. Hims/Hers feature by feature
Based on publicly available data, pricing pages, and patient reviews — April 2026.
| Feature | REMEVi | Hims / Hers |
|---|---|---|
| GLP-1 best price | ✅ From $199/mo (52-week) — all-in | ~$199/mo + ongoing fees |
| Spanish language support | ✅ Fully bilingual (built-in) | ❌ English only |
| Women's health | ✅ Full program from day one | ✅ Limited (Hers brand) |
| Data security | ✅ 0 breaches ever | ⚠️ Reported incidents |
| Hidden fees | ✅ None — all-inclusive | ⚠️ Lab fees, add-ons |
| Support response time | ✅ 2-hour SLA guaranteed | ❌ 24–48 hours typical |
| LegitScript certified | ✅ Certified | ✅ Certified |
| Bilingual care coordinator | ✅ Assigned to every patient | ❌ Not offered |
Pricing and features subject to change. Always verify current pricing on each provider's website.
The bilingual difference
Built bilingual — not retrofitted
Hims/Hers operates exclusively in English. REMEVi was built bilingual from the ground up. Every intake form, provider note, care coordinator message, and patient touchpoint is available in fluent English and Spanish.
GLP-1 programs
How the GLP-1 programs compare
Both REMEVi and Hims/Hers offer compounded semaglutide and tirzepatide for weight loss. The active pharmaceutical ingredients are the same — what differs is the experience around the medication: pricing structure, care team access, language support, and response time.
On pricing: REMEVi starts at $199/month on the 52-week plan ($279/month on month-to-month), all-inclusive. Hims typically prices GLP-1 plans at approximately $199/month and may charge separately for lab work or quarterly consultations. Always verify current pricing directly on each provider's site, as telehealth pricing changes frequently.
On support: REMEVi assigns every patient a dedicated bilingual care coordinator with a 2-hour response SLA. Hims/Hers operates primarily through asynchronous messaging with no guaranteed response time. For patients managing side effects, dosage questions, or medication concerns, response time matters significantly.
On clinical oversight: Both platforms use licensed US providers for prescribing. REMEVi licensed providers are licensed in the patient's specific state. Prescription approval typically occurs within 24 hours on both platforms.
On language: This is where the platforms diverge completely. Hims/Hers operates exclusively in English. REMEVi's entire platform — intake forms, clinical summaries, medication instructions, care coordinator communications — is available natively in English and Spanish. For the 62 million Spanish-speaking Americans, this is not a minor feature. It is a fundamental difference in the quality of care they receive.
FAQ
Common questions
Yes. REMEVi's GLP-1 program starts at $199/month on a 52-week plan ($279/month on month-to-month) — all-inclusive: clinical review, medication, shipping, and support are included. Hims typically prices GLP-1 plans in a similar range but may charge additional fees for labs or consultations.
Hims/Hers currently offers services in English only. REMEVi is the only telehealth platform in the US built natively bilingual — every intake form, care coordinator, and patient message is available in English and Spanish from day one.
Hers (the sister brand) offers some women's health services. However, REMEVi provides a comprehensive women's program — including HRT, hair regrowth, skin health, and mental health — all in one place, with bilingual support.
Both offer compounded semaglutide. REMEVi differentiates with lower pricing, bilingual support, and a 2-hour response SLA. For Spanish-speaking patients, REMEVi is the clear choice.
Yes. Switching is straightforward — complete REMEVi's 5-minute intake form, a clinical reviews your case within 24 hours, and your medication ships within days. You do not need to formally cancel Hims before starting with REMEVi. Simply time your transition to avoid overlapping charges.
Both REMEVi and Hims offer compounded semaglutide and compounded tirzepatide prescribed by licensed US providers and prepared by state-licensed compounding pharmacies. Compounded medications are non-FDA-approved preparations and are not generic versions of, nor the same as, Ozempic®, Wegovy®, Mounjaro®, or Zepbound®. REMEVi differs from Hims on bilingual support, response SLA, and pricing transparency.
Both platforms have licensed providers available to address side effect concerns. REMEVi's 2-hour response SLA from a bilingual care coordinator means you get faster human support when managing nausea, fatigue, or dosage concerns — common in the first weeks of GLP-1 therapy.
Ready to get started with REMEVi?
Clinical review in 24 hours. No insurance needed. From $199/mo on 52-week plan, all-inclusive.
Start free consultation